Skip to main content
Clinical Trials/NCT04050618
NCT04050618
Completed
Not Applicable

Multi-Center Cross-Over Evaluation Of Avaira Vitality Silicone Hydrogel Contact Lens and Two Hydrogel Lenses in Daily Wear

Coopervision, Inc.6 sites in 1 country114 target enrollmentJune 9, 2019
ConditionsMyopia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myopia
Sponsor
Coopervision, Inc.
Enrollment
114
Locations
6
Primary Endpoint
Subjective Overall Comfort Rating
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

To evaluate the comparative clinical performance of the fanfilcon A silicone hydrogel lens used in daily wear and to compare this with competitive hydrogel lens products.

Detailed Description

This 8-week, subject-masked, bilateral, two-part, cross-over evaluation will compare the clinical performance of fanfilcon A silicone hydrogel contact lens and competitive hydrogel contact lenses when worn daily. Lenses will be replaced either on a 2-weekly or 4-weekly basis, depending on control lens group.

Registry
clinicaltrials.gov
Start Date
June 9, 2019
End Date
November 8, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Be a currently adapted soft contact lens wearer (\>1 month of lens wear).
  • Be at least 18 years of age.
  • Refractive astigmatism \<1.00D in both eyes.
  • Have clear corneas and be free of any anterior segment disorders.
  • Be correctable through spherocylindrical refraction to 20/25 or better in each eye.
  • Contact lens sphere requirement between -1.00D and -6.00D (inclusive).
  • Require visual correction in both eyes (monovision allowed, no monofit).
  • Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
  • No amblyopia
  • No strabismus

Exclusion Criteria

  • Using CooperVision Avaira Vitality, J\&J Acuvue 2 or CooperVision Biomedics
  • Require toric or multifocal contact lenses.
  • Previously shown a sensitivity to any of the study solution components.
  • Any systemic or ocular disease or allergies affecting ocular health.
  • Using systemic or topical medications that will in the investigator's opinion affect ocular physiology or lens performance.
  • Clinically significant (\>Grade 3) corneal staining, corneal stromal edema, corneal vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear.
  • Any corneal infiltrates or any corneal scarring or neovascularization within the central 5mm of the cornea.
  • Keratoconus or other corneal irregularity.
  • Aphakia or amblyopia.
  • Have undergone corneal refractive surgery or any anterior segment surgery.

Outcomes

Primary Outcomes

Subjective Overall Comfort Rating

Time Frame: Four weeks

Subjective overall comfort rating was assessed on a 0-10 subjective scale, 0=extremely uncomfortable, 10=can't feel lenses

Secondary Outcomes

  • Average Wearing Time(Four weeks)
  • Average Comfortable Wearing Time(Four weeks)
  • Lens Centration(Four weeks)
  • Corneal Coverage(Four weeks)
  • Post-Blink Movement(Four weeks)
  • Lens Tightness - Push-up Test(Four weeks)
  • Overall Lens Fit Acceptance(Four weeks)
  • Rating of Lens Surface Wettability(Four weeks)
  • Presence of Film Deposits(Four weeks)
  • Number of White Spot Deposits(Four weeks)
  • Primary Gaze Lag(Four weeks)
  • Comfort Throughout the Day(Day 26 - 8:00pm)

Study Sites (6)

Loading locations...

Similar Trials